-
Something wrong with this record ?
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study
E. Clemens, AJ. Meijer, L. Broer, T. Langer, AL. van der Kooi, AG. Uitterlinden, A. de Vries, CE. Kuehni, ML. Garrè, T. Kepak, J. Kruseova, JF. Winther, LC. Kremer, E. van Dulmen-den Broeder, WJ. Tissing, C. Rechnitzer, L. Kenborg, H. Hasle, D....
Language English Country Canada
Document type Journal Article
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Nursing & Allied Health Database (ProQuest)
from 2012-01-01
Health & Medicine (ProQuest)
from 2012-01-01
Public Health Database (ProQuest)
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
30888333
DOI
10.2196/11868
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However, results were inconsistent and most studies were underpowered and/or lacked replication. OBJECTIVE: We describe the design of the PanCareLIFE consortium's work packages that address the genetic susceptibility of platinum-induced ototoxicity. METHODS: As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a candidate gene approach and a genome-wide association screening. RESULTS: This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer, resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided, for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses and the first results are expected by the end of 2019 or the beginning of 2020. CONCLUSIONS: Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/11868.
Boyne Research Institute Drogheda Ireland
Danish Cancer Society Research Center Copenhagen Denmark
Department of Internal Medicine Erasmus Medical Center Rotterdam Netherlands
Department of Neurooncology Institute Giannina Gaslini Genova Italy
Department of Pediatric Hemato Oncology Motol University Hospital Prague Prague Czech Republic
Department of Pediatric Oncology University Hospital for Children and Adolescents Luebeck Germany
Department of Pediatrics Aarhus University Hospital Aarhus Denmark
Department of Phoniatrics and Pedaudiology University of Münster Muenster Germany
Princess Maxima Center for Pediatric Oncology Utrecht Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013236
- 003
- CZ-PrNML
- 005
- 20190412102412.0
- 007
- ta
- 008
- 190405s2019 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2196/11868 $2 doi
- 035 __
- $a (PubMed)30888333
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Clemens, Eva $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Hematology and Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands.
- 245 10
- $a Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study / $c E. Clemens, AJ. Meijer, L. Broer, T. Langer, AL. van der Kooi, AG. Uitterlinden, A. de Vries, CE. Kuehni, ML. Garrè, T. Kepak, J. Kruseova, JF. Winther, LC. Kremer, E. van Dulmen-den Broeder, WJ. Tissing, C. Rechnitzer, L. Kenborg, H. Hasle, D. Grabow, R. Parfitt, H. Binder, BC. Carleton, J. Byrne, P. Kaatsch, A. Am Zehnhoff-Dinnesen, O. Zolk, MM. van den Heuvel-Eibrink,
- 520 9_
- $a BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However, results were inconsistent and most studies were underpowered and/or lacked replication. OBJECTIVE: We describe the design of the PanCareLIFE consortium's work packages that address the genetic susceptibility of platinum-induced ototoxicity. METHODS: As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a candidate gene approach and a genome-wide association screening. RESULTS: This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer, resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided, for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses and the first results are expected by the end of 2019 or the beginning of 2020. CONCLUSIONS: Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/11868.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Meijer, Annelot Jm $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
- 700 1_
- $a Broer, Linda $u Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
- 700 1_
- $a Langer, Thorsten $u Department of Pediatric Oncology, University Hospital for Children and Adolescents, Luebeck, Germany.
- 700 1_
- $a van der Kooi, Anne-Lotte Lf $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Hematology and Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands. Department of Obstetrics and Gynecology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands.
- 700 1_
- $a Uitterlinden, André G $u Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
- 700 1_
- $a de Vries, Andrica $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Hematology and Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands.
- 700 1_
- $a Kuehni, Claudia E $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Department of Paediatric Respiratory Medicine, University Children's Hospital, University of Bern, Bern, Switzerland.
- 700 1_
- $a Garrè, Maria L $u Department of Neurooncology, Institute Giannina Gaslini, Genova, Italy.
- 700 1_
- $a Kepak, Tomas $u Department of Paediatric Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic. St. Anne's University Hospital Brno-International Clinical Research Center, Brno, Czech Republic.
- 700 1_
- $a Kruseova, Jarmila $u Department of Pediatric Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
- 700 1_
- $a Winther, Jeanette F $u Danish Cancer Society Research Center, Copenhagen, Denmark. Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
- 700 1_
- $a Kremer, Leontien C $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, Netherlands.
- 700 1_
- $a van Dulmen-den Broeder, Eline $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Hematology and Oncology, VU Medical Center, Amsterdam, Netherlands.
- 700 1_
- $a Tissing, Wim Je $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Rechnitzer, Catherine $u Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Kenborg, Line $u Danish Cancer Society Research Center, Copenhagen, Denmark.
- 700 1_
- $a Hasle, Henrik $u Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
- 700 1_
- $a Grabow, Desiree $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- 700 1_
- $a Parfitt, Ross $u Department of Phoniatrics and Pedaudiology, University of Münster, Muenster, Germany.
- 700 1_
- $a Binder, Harald $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freibug, Germany.
- 700 1_
- $a Carleton, Bruce C $u Division of Translational Therapeutics, Department of Pediatrics, British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
- 700 1_
- $a Byrne, Julianne $u Boyne Research Institute, Drogheda, Ireland.
- 700 1_
- $a Kaatsch, Peter $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- 700 1_
- $a Am Zehnhoff-Dinnesen, Antoinette $u Department of Phoniatrics and Pedaudiology, University of Münster, Muenster, Germany.
- 700 1_
- $a Zolk, Oliver $u Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany.
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
- 773 0_
- $w MED00193519 $t JMIR research protocols $x 1929-0748 $g Roč. 8, č. 3 (2019), s. e11868
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30888333 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190412102431 $b ABA008
- 999 __
- $a ind $b bmc $g 1392546 $s 1051541
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 8 $c 3 $d e11868 $e 20190319 $i 1929-0748 $m JMIR research protocols $n JMIR Res Protoc $x MED00193519
- LZP __
- $a Pubmed-20190405
